Gene Therapy MCQ Exam! Quiz

Gene therapy is a medical treatment that aims to treat disorders and diseases that are caused by inheritance. It involves introducing genetic material into a person's cells to correct or replace a faulty gene. This can help to prevent or alleviate the symptoms of genetic disorders and diseases. By targeting the root cause of these conditions, gene therapy offers the potential for long-term and potentially permanent treatments.

Gene therapy is not an example of either asexual or sexual reproduction because it does not involve the creation of new organisms or the transfer of genetic material between individuals. Instead, gene therapy involves the introduction or modification of genes within an individual's cells to treat or prevent disease. It is a medical technique rather than a reproductive process.

William French Anderson is credited with inventing gene therapy. He is known as the "father of gene therapy" for his pioneering work in the field. In 1990, Anderson and his team successfully treated a patient with a genetic disorder using gene therapy, marking a significant milestone in medical history. His groundbreaking research and contributions have paved the way for the development and advancement of gene therapy as a potential treatment for various genetic diseases.

Gene therapy is a medical technique that involves altering or replacing faulty genes in order to treat or prevent diseases. It has shown promising results in curing deadly diseases such as cancer, cystic fibrosis, and certain genetic disorders. By correcting the underlying genetic defect, gene therapy aims to eliminate or reduce the symptoms of these life-threatening conditions. Therefore, the answer "Deadly Diseases" is the correct one as gene therapy is primarily used for the treatment of such illnesses.

The thymidine kinase (TK) gene from the herpes simplex virus (HSV) has an enzymatic property that converts the drug ganciclovir into a toxic substance that can kill human dividing cells.

The correct answer is that the retrovirus inserted near a proto-oncogene promoter. This means that the retrovirus inserted itself into the DNA near a region that controls the expression of an oncogene, which can lead to the development of cancer. This insertion likely caused the boy to develop a leukemia-like condition.

Insertional mutagenesis is not a risk factor in gene therapy using adenoviruses. Insertional mutagenesis refers to the insertion of the therapeutic gene into the host genome, which can potentially disrupt normal gene function and lead to the development of cancer or other genetic abnormalities. However, adenoviruses are non-integrating vectors, meaning they do not integrate their DNA into the host genome. Therefore, the risk of insertional mutagenesis is low in adenovirus-based gene therapy.

Oncorine is not a product name for a replication-deficient adenoviral vector containing the p53 gene. Gendicine, Advexin, and SCH58500 are all examples of product names for such vectors, but Oncorine is not.

Pseudotyped viruses are referred to as viruses in which their envelope proteins have been replaced by other proteins, like VSV-G, to increase the tropism. This means that the original envelope proteins of the virus have been substituted with different proteins, allowing the virus to target and infect specific cell types that it normally couldn't. These pseudotyped viruses maintain their ability to infect cells, but with enhanced specificity due to the new envelope proteins.

The first patient who died during a gene therapy experiment in 1999 was attempting to treat Ornithine transcarbamylase deficiency.